Oral regimen for multi-drug-resistant TB can promote patient-centred and community-based treatment.
作者信息
Saurabh Suman, Bhardwaj Pankaj
机构信息
Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India.
出版信息
J Family Med Prim Care. 2021 Dec;10(12):4607-4608. doi: 10.4103/jfmpc.jfmpc_2502_20. Epub 2021 Dec 27.
Abstract
摘要
相似文献
1
Oral regimen for multi-drug-resistant TB can promote patient-centred and community-based treatment.耐多药结核病的口服治疗方案可促进以患者为中心和基于社区的治疗。
J Family Med Prim Care. 2021 Dec;10(12):4607-4608. doi: 10.4103/jfmpc.jfmpc_2502_20. Epub 2021 Dec 27.
2
Person-centred care in practice: perspectives from a short course regimen for multi-drug resistant tuberculosis in Karakalpakstan, Uzbekistan.实践中的以患者为中心的护理：来自乌兹别克斯坦卡拉卡尔帕克斯坦耐多药结核病短期课程方案的观点。
BMC Infect Dis. 2020 Sep 16;20(1):675. doi: 10.1186/s12879-020-05407-7.
3
Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.尼日利亚利福平耐药/耐多药结核病 9 个月治疗方案与 20 个月标准化护理成本比较。
PLoS One. 2020 Dec 1;15(12):e0241065. doi: 10.1371/journal.pone.0241065. eCollection 2020.
4
Developing a patient-centered community-based model for management of multi-drug resistant tuberculosis in Uganda: a discrete choice experiment.在乌干达开发以患者为中心的社区为基础的耐多药结核病管理模式：离散选择实验。
BMC Health Serv Res. 2022 Feb 5;22(1):154. doi: 10.1186/s12913-021-07365-5.
5
Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis.耐多药和广泛耐药结核病。
Indian J Pediatr. 2020 Oct;87(10):833-839. doi: 10.1007/s12098-020-03230-1. Epub 2020 Feb 26.
6
Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan.乌兹别克斯坦卡拉卡尔帕克斯坦短程耐多药结核病治疗效果建模
BMC Med. 2016 Nov 18;14(1):187. doi: 10.1186/s12916-016-0723-2.
7
A case report of a child with probable drug resistant tuberculous pericarditis with a review of challenges involved in diagnosis, treatment and follow up of children with DR-TB pericarditis.一例疑似耐药结核性心包炎患儿病例报告，并对儿童耐多药结核性心包炎的诊断、治疗和随访中所涉及的挑战进行了回顾。
BMC Infect Dis. 2020 Apr 22;20(1):298. doi: 10.1186/s12879-020-05027-1.
8
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.地拉米胺、利奈唑胺、左氧氟沙星和吡嗪酰胺用于治疗氟喹诺酮敏感的耐多药结核病患者（使用现有和新药缩短耐多药结核病治疗时间，MDR-END）：一项II/III期、多中心、随机、开放标签临床试验的研究方案
Trials. 2019 Jan 16;20(1):57. doi: 10.1186/s13063-018-3053-1.
9
Is effective patient support missing in the global response to multidrug-resistant tuberculosis?在全球应对耐多药结核病的行动中，是否缺少有效的患者支持？
Int J Tuberc Lung Dis. 2020 Jun 1;24(6):626-630. doi: 10.5588/ijtld.19.0529.
10
Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.韩国耐多药结核病患者的额外耐药模式：对治疗方案设计的启示
J Korean Med Sci. 2017 Apr;32(4):636-641. doi: 10.3346/jkms.2017.32.4.636.
本文引用的文献
1
Diagnosis and treatment of multidrug-resistant tuberculosis.耐多药结核病的诊断与治疗
Yeungnam Univ J Med. 2020 Oct;37(4):277-285. doi: 10.12701/yujm.2020.00626. Epub 2020 Sep 4.
2
What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?世界卫生组织耐药结核病治疗综合指南中有哪些新内容？
Indian J Med Res. 2019 Mar;149(3):309-312. doi: 10.4103/ijmr.IJMR_579_19.
3
Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis.迈向耐药结核病的全口服及更短疗程治疗方案。
Bull World Health Organ. 2018 Oct 1;96(10):667-667A. doi: 10.2471/BLT.18.223230.
4
Emergence of fluoroquinolone resistance among drug resistant tuberculosis patients at a tertiary care facility in Karachi, Pakistan.巴基斯坦卡拉奇一家三级医疗机构中耐药结核病患者对氟喹诺酮耐药情况的出现。
BMC Res Notes. 2017 Jul 25;10(1):313. doi: 10.1186/s13104-017-2633-6.
Zotero 插件